Journal of Medicinal Chemistry p. 1105 - 1131 (2020)
Update date:2022-08-15
Topics:
Kienle, Maryline
Eisenring, Patrick
Stoessel, Barbara
Horlacher, Oliver P.
Hasler, Samuel
Van Colen, Gwéna?lle
Hartkoorn, Ruben C.
Vocat, Anthony
Cole, Stewart T.
Altmann, Karl-Heinz
A series of derivatives of the antimycobacterial natural product pyridomycin have been prepared with the C2 side chain attached to the macrocyclic core structure by a C-C single bond, in place of the synthetically more demanding enol ester double bond found in the natural product. Hydrophobic C2 substituents of sufficient size generally provide for potent anti-Mtb activity of these dihydropyridomycins (minimum inhibitory concentration (MIC) values around 2.5 μM), with several analogs thus approaching the activity of natural pyridomycin. Surprisingly, some of these compounds, in contrast to pyridomycin, are insensitive to overexpression of InhA in Mycobacterium tuberculosis (Mtb). This indicates that their anti-Mtb activity does not critically depend on the inhibition of InhA and that their overall mode of action may differ from that of the original natural product lead.
View MoreHunan Dinuo Pharmaceutical Co.,Ltd.
Contact:86-731-88280100*8561
Address:Bio-pharmaceutical industrial park, Liuyang, Hunan, China
Nanjing Habo Medical Technology Co., Ltd.
Contact:025-85769882
Address:No.108. Ganjiabian east. Qixia District .Nanjing
Shanxi Tongji Pharmaceuticals Co., Ltd.
Contact:+86-359-3024784
Address:Xikuang South Road, Ruicheng County , Shanxi
Shanghai Dano Pharmaceutical Co.,Ld.(expird)
Contact:+86-592-6266840
Address:Building 1 Room 512, 720 Cailun Rd, Zhangjiang High-Tech Park, Shanghai 201203, China
Contact:
Address:308# dongwu avenue dongxihu district wuhan city
Doi:10.1016/0960-894X(96)00427-1
(1996)Doi:10.1021/ja01854a051
(1941)Doi:10.1039/CC9960002179
(1996)Doi:10.1002/anie.200600572
(2006)Doi:10.1021/np050378g
(2006)Doi:10.1002/zaac.19683630110
(1968)